Catalogo Articoli (Spogli Riviste)

HELP
ATTENZIONE: attualmente gli articoli Current Contents (fonte ISI) a partire dall'anno 2002 sono consultabili sulla Risorsa On-Line

Le informazioni sugli articoli di fonte ISI sono coperte da copyright

La ricerca find articoli where authors phrase all words ' Sartor, O' sort by level,fasc_key/DESCEND, pagina_ini_num/ASCEND ha restituito 53 riferimenti
Selezionare un intervallo

Per ulteriori informazioni selezionare i riferimenti di interesse.

    1. Schmitt, B; Wilt, TJ; Schellhammer, PF; DeMasi, V; Sartor, O; Crawford, ED; Bennett, CL
      Combined androgen blockade with nonsteroidal antiandrogens for advanced prostate cancer: A systematic review

      UROLOGY
    2. Sartor, O; McLeod, D
      Indium-111-capromab pendetide scans: An important test relevant to clinical decision making

      UROLOGY
    3. Jani, AB; Vaida, F; Hanks, G; Asbell, S; Sartor, O; Moul, JW; Roach, M; Brachman, D; Kalokhe, U; Muller-Runkel, R; Ray, P; Ignacio, L; Awan, A; Weichselbaum, RR; Vijayakumar, S
      Changing face and different countenances of prostate cancer: Racial and geographic differences in prostate-specific antigen (PSA), stage, and grade trends in the PSA era

      INTERNATIONAL JOURNAL OF CANCER
    4. Small, EJ; Figlin, R; Petrylak, D; Vaughn, DJ; Sartor, O; Horak, I; Pincus, R; Kremer, A; Bowden, C
      A phase II pilot study of KW-2189 in patients with advanced renal cell carcinoma

      INVESTIGATIONAL NEW DRUGS
    5. Bubley, GJ; Carducci, M; Dahut, W; Dawson, N; Daliani, D; Eisenberger, M; Figg, WD; Freidlin, B; Halabi, S; Hudes, G; Hussain, M; Kaplan, R; Myers, C; Oh, W; Petrylak, DP; Reed, E; Roth, B; Sartor, O; Scher, H; Simons, J; Sinibaldi, V; Small, EJ; Smith, MR; Trump, DL; Vollmer, R; Wilding, G
      Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: Recommendations from the prostate-specific antigen working group

      JOURNAL OF CLINICAL ONCOLOGY
    6. Eastham, JA; May, R; Robertson, JL; Sartor, O; Kattan, MW
      Development of a nomogram that predicts the probability of a positive prostate biopsy in men with an abnormal digital rectal examination and a prostate-specific antigen between 0 and 4 ng/mL

      UROLOGY
    7. Kubricht, WS; Kattan, MW; Sartor, O; Eastham, JA
      Race is not independently associated with a positive prostate biopsy in men suspected of having prostate cancer

      UROLOGY
    8. Sartor, O; Zheng, Q; Eastham, JA
      Androgen receptor gene CAG repeat length varies in a race-specific fashionin men without prostate cancer

      UROLOGY
    9. Sartor, O; Eastham, JA
      Progressive prostate cancer associated with use of megestrol acetate administered for control of hot flashes

      SOUTHERN MEDICAL JOURNAL
    10. Figg, WD; Pluda, JM; Sartor, O
      Pentosan polysulfate - A polysaccharide that inhibits angiogenesis by binding growth factors

      ANTIANGIOGENIC AGENTS IN CANCER THERAPY
    11. FEUER JA; LUSH RM; VENZON D; DURAY P; TOMPKINS A; SARTOR O; FIGG WD
      ELEVATED CARCINOEMBRYONIC ANTIGEN IN PATIENTS WITH ANDROGEN-INDEPENDENT PROSTATE-CANCER

      Journal of investigative medicine
    12. DAWSON N; FIGG WD; BRAWLEY OW; BERGAN R; COOPER MR; SENDEROWICZ A; HEADLEE D; STEINBERG SM; SUTHERLAND M; PATRONAS N; SAUSVILLE E; LINEHAN WM; REED E; SARTOR O
      PHASE-II STUDY OF SURAMIN PLUS AMINOGLUTETHIMIDE IN 2 COHORTS OF PATIENTS WITH ANDROGEN-INDEPENDENT PROSTATE-CANCER - SIMULTANEOUS ANTIANDROGEN WITHDRAWAL AND PRIOR ANTIANDROGEN WITHDRAWAL

      Clinical cancer research
    13. DAWSON N; FIGG WD; BRAWLEY OW; BERGAN R; COOPER MR; SENDEROWICZ A; HEADLEE D; STEINBERG SM; SUTHERLAND M; PATRONAS N; SAUSVILLE E; LINEHAN WM; REED E; SARTOR O
      PHASE-II STUDY OF SURAMIN PLUS AMINOGLUTETHIMIDE IN 2 COHORTS OF PATIENTS WITH ANDROGEN-INDEPENDENT PROSTATE-CANCER - SIMULTANEOUS ANTIANDROGEN WITHDRAWAL AND PRIOR ANTIANDROGEN WITHDRAWAL

      Clinical cancer research
    14. HORTI J; FIGG WD; WEINBERGER B; KOHLER D; SARTOR O
      A PHASE-II STUDY OF BROMOCRIPTINE IN PATIENTS WITH ANDROGEN-INDEPENDENT PROSTATE-CANCER

      Oncology Reports
    15. BOILEAU T; FERRUZZI M; SARTOR O; SCHWARTZ S; ERDMAN J; CLINTON S
      LYCOPENE ISOMERS AND CAROTENOID PROFILES IN AFRICAN-AMERICAN (AA) ANDCAUCASIAN (C) MEN

      The FASEB journal
    16. BENNETT CL; FERREIRA MR; DAVIS TC; KAPLAN J; WEINBERGER M; KUZEL T; SEDAY MA; SARTOR O
      RELATION BETWEEN LITERACY, RACE, AND STAGE OF PRESENTATION AMONG LOW-INCOME PATIENTS WITH PROSTATE-CANCER

      Journal of clinical oncology
    17. SARTOR O; WEINBERGER M; MOORE A; LI AL; FIGG WD
      EFFECT OF PREDNISONE ON PROSTATE-SPECIFIC ANTIGEN IN PATIENTS WITH HORMONE-REFRACTORY PROSTATE-CANCER

      Urology
    18. SARTOR O; EASTHAM JA; VENABLE DD; WILLIAMS P
      RACIAL VARIATION IN PSA IN A WELL-DEFINED COHORT OF MEN WITHOUT KNOWNPROSTATE-CANCER

      The Journal of urology
    19. VANBINGHAM W; EASTHAM JA; SARTOR O; FIGG WD
      LACK OF GLEASONS SUM EFFECT ON SURVIVAL IN PATIENTS WITH STAGE D2 PROSTATE-CANCER

      The Journal of urology
    20. EASTHAM JA; SARTOR O
      NILUTAMIDE RESPONSE AFTER FLUTAMIDE FAILURE IN POSTORCHIECTOMY PROGRESSIVE PROSTATE-CANCER

      The Journal of urology
    21. EASTHAM JA; MAY RA; WHATLEY T; CROW A; VENABLE DD; SARTOR O
      CLINICAL CHARACTERISTICS AND BIOPSY SPECIMEN FEATURES IN AFRICAN-AMERICAN AND WHITE MEN WITHOUT PROSTATE-CANCER

      Journal of the National Cancer Institute
    22. DAWSON NA; FIGG WD; COOPER MR; SARTOR O; BERGAN RC; SENDEROWICZ AM; STEINBERG SM; TOMPKINS A; WEINBERGER B; SAUSVILLE EA; REED E; MYERS CE
      PHASE-II TRIAL OF SURAMIN, LEUPROLIDE, AND FLUTAMIDE IN PREVIOUSLY UNTREATED METASTATIC PROSTATE-CANCER

      Journal of clinical oncology
    23. SARTOR O; ZHENG Q
      DETERMINATION OF CAG REPEAT LENGTH IN THE ANDROGEN-RECEPTOR GENE USING FROZEN SERUM

      Urology
    24. WILLIAMS PB; EASTHAM JA; CULKIN DJ; MATA JA; VENABLE DD; SARTOR O
      INFLUENCE OF HEPATIC-FUNCTION ON SERUM LEVELS OF PROSTATE-SPECIFIC ANTIGEN

      The Journal of urology
    25. FIGG WD; KROOG G; DURAY P; WALTHER MM; PATRONAS N; SARTOR O; REED E
      FLUTAMIDE WITHDRAWAL PLUS HYDROCORTISONE RESULTED IN CLINICAL COMPLETE RESPONSE IN A PATIENT WITH PROSTATE CARCINOMA

      Cancer
    26. HENDERSON RJ; EASTHAM JA; CULKIN DJ; KATTAN MW; WHATLEY T; MATA J; VENABLE D; SARTOR O
      PROSTATE-SPECIFIC ANTIGEN (PSA) AND PSA DENSITY - RACIAL-DIFFERENCES IN MEN WITHOUT PROSTATE-CANCER

      Journal of the National Cancer Institute
    27. LUSH RM; FIGG WD; PLUDA JM; BITTON R; HEADLEE D; KOHLER D; REED E; SARTOR O; COOPER MR
      A PHASE-I STUDY OF PENTOSAN POLYSULFATE SODIUM IN PATIENTS WITH ADVANCED MALIGNANCIES

      Annals of oncology
    28. FIGG WD; AMMERMAN K; PATRONAS N; STEINBERG SM; WALLS RG; DAWSON N; REED E; SARTOR O
      LACK OF CORRELATION BETWEEN PROSTATE-SPECIFIC ANTIGEN AND THE PRESENCE OF MEASURABLE SOFT-TISSUE METASTASES IN HORMONE-REFRACTORY PROSTATE-CANCER

      Cancer investigation
    29. BOWDEN CJ; FIGG WD; DAWSON NA; SARTOR O; BITTON RJ; WEINBERGER MS; HEADLEE D; REED E; MYERS CE; COOPER MR
      A PHASE I II STUDY OF CONTINUOUS-INFUSION SURAMIN IN PATIENTS WITH HORMONE-REFRACTORY PROSTATE-CANCER - TOXICITY AND RESPONSE/

      Cancer chemotherapy and pharmacology
    30. MIDDLEMAN MN; LUSH RM; SARTOR O; REED E; FIGG WD
      TREATMENT APPROACHES FOR METASTATIC CANCER OF THE PROSTATE BASED ON RECENT MOLECULAR EVIDENCE

      Cancer treatment reviews
    31. FIGG WD; DAWSON N; MIDDLEMAN MN; BRAWLEY O; LUSH RM; SENDEROWICZ A; STEINBERG SH; TOMPKINS A; REED E; SARTOR O
      FLUTAMIDE WITHDRAWAL AND CONCOMITANT INITIATION OF AMINOGLUTETHIMIDE IN PATIENTS WITH HORMONE-REFRACTORY PROSTATE-CANCER

      Acta oncologica
    32. SARTOR O; FIGG WD
      MIFEPRISTONE - ANTINEOPLASTIC STUDIES

      Clinical obstetrics and gynecology
    33. SARTOR O; CUTLER GB
      MIFEPRISTONE - TREATMENT OF CUSHINGS-SYNDROME

      Clinical obstetrics and gynecology
    34. FIGG WD; MIDDLEMAN MN; SARTOR O
      THERAPEUTIC OPTIONS IN PATIENTS WITH HORMONE-REFRACTORY PROSTATE-CANCER - REPLY

      The American journal of medicine
    35. SARTOR O
      PROSTATE-SPECIFIC ANTIGEN CHANGES BEFORE AND AFTER ADMINISTRATION OF AN ANGIOGENESIS INHIBITOR (TNP-470)

      Oncology Reports
    36. FIGG WD; MCCALL NA; REED E; SARTOR O
      THE IN-VITRO RESPONSE OF 4 ANTISTEROID RECEPTOR AGENTS ON THE HORMONE-RESPONSIVE PROSTATE-CANCER CELL-LINE LNCAP

      Oncology Reports
    37. SARTOR BM; SARTOR O; FLANDERS KC
      ANALOGOUS TAMOXIFEN AND ESTROGEN EFFECTS ON TRANSFORMING GROWTH-FACTOR-BETA-1 AND GROWTH-FACTOR-BETA-2 IN THE RAT UTERUS

      Reproductive toxicology
    38. SARTOR O; VENABLE D; MATA J
      RACIAL-DIFFERENCES IN RADICAL PROSTATECTOMY

      Journal of clinical oncology
    39. FIGG WD; MIDDLEMAN M; SARTOR O
      MUTATED ANDROGEN RECEPTORS OF PROSTATE-CANCER CELLS

      The New England journal of medicine
    40. BORNER MM; MYERS CE; SARTOR O; SEI Y; TOKO T; TREPEL JB; SCHNEIDER E
      DRUG-INDUCED APOPTOSIS IS NOT NECESSARILY DEPENDENT ON MACROMOLECULAR-SYNTHESIS OR PROLIFERATION IN THE P53-NEGATIVE HUMAN PROSTATE-CANCER CELL-LINE PC-3

      Cancer research
    41. DAWSON NA; COOPER MR; FIGG WD; HEADLEE DJ; THIBAULT A; BERGAN RC; STEINBERG SM; SAUSVILLE EA; MYERS CE; SARTOR O
      ANTITUMOR-ACTIVITY OF SURAMIN IN HORMONE-REFRACTORY PROSTATE-CANCER CONTROLLING FOR HYDROCORTISONE TREATMENT AND FLUTAMIDE WITHDRAWAL AS POTENTIALLY CONFOUNDING VARIABLES

      Cancer
    42. FIGG WD; THIBAULT A; COOPER MR; REID R; HEADLEE D; DAWSON N; KOHLER DR; REED E; SARTOR O
      A PHASE-I STUDY OF THE SOMATOSTATIN ANALOG SOMATULINE IN PATIENTS WITH METASTATIC HORMONE-REFRACTORY PROSTATE-CANCER

      Cancer
    43. FIGG WD; SARTOR O; COOPER MR; THIBAULT A; BERGAN RC; DAWSON N; REED E; MYERS CE
      PROSTATE-SPECIFIC ANTIGEN DECLINE FOLLOWING THE DISCONTINUATION OF FLUTAMIDE IN PATIENTS WITH STAGE D2 PROSTATE-CANCER

      The American journal of medicine
    44. FIGG WD; WALLS RG; COOPER MR; THIBAULT A; SARTOR O; MCCALL NA; MYERS CE; SAMID D
      IN-VITRO ANTITUMOR EFFECT OF HYDROXYUREA ON HORMONE-REFRACTORY PROSTATE-CANCER CELLS AND ITS POTENTIATION BY PHENYLBUTYRATE

      Anti-cancer drugs
    45. BANG YJ; PIRNIA F; FANG WG; KANG WK; SARTOR O; WHITESELL L; HA MJ; TSOKOS M; SHEAHAN MD; NGUYEN P; NIKLINSKI WT; MYERS CE; TREPEL JB
      TERMINAL NEUROENDOCRINE DIFFERENTIATION OF HUMAN PROSTATE CARCINOMA-CELLS IN RESPONSE TO INCREASED INTRACELLULAR CYCLIC-AMP

      Proceedings of the National Academy of Sciences of the United Statesof America
    46. BORNER MM; SCHNEIDER E; PIRNIA F; SARTOR O; TREPEL JB; MYERS CE
      THE DETERGENT TRITON X-100 INDUCES A DEATH PATTERN IN HUMAN CARCINOMACELL-LINES THAT RESEMBLES CYTOTOXIC LYMPHOCYTE-INDUCED APOPTOSIS

      FEBS letters
    47. FIGG WD; COOPER MR; THIBAULT A; HEADLEE D; HUMPHREY J; BERGAN R; REED E; SARTOR O
      ACUTE RENAL TOXICITY ASSOCIATED WITH SURAMIN IN THE TREATMENT OF PROSTATE-CANCER

      Cancer
    48. SARTOR O; COOPER MR; KHLEIF SN; MYERS CE
      SURAMIN DECREASES CIRCULATING LEVELS OF INSULIN-LIKE GROWTH-FACTOR-I

      The American journal of medicine
    49. SARTOR O; COOPER M; WEINBERGER M
      SURPRISING ACTIVITY OF FLUTAMIDE WITHDRAWAL, WHEN COMBINED WITH AMINOGLUTETHIMIDE, IN TREATMENT OF HORMONE-REFRACTORY PROSTATE-CANCER (VOL 86, PG 222, 1994)

      Journal of the National Cancer Institute
    50. SARTOR O; COOPER M; WEINBERGER M; HEADLEE D; THIBAULT A; TOMPKINS A; STEINBERG S; FIGG WD; LINEHAN WM; MYERS CE
      SURPRISING ACTIVITY OF FLUTAMIDE WITHDRAWAL, WHEN COMBINED WITH AMINOGLUTETHIMIDE, IN TREATMENT OF HORMONE-REFRACTORY PROSTATE-CANCER

      Journal of the National Cancer Institute
    51. BORNER MM; SARTOR O
      RESPONSE TO MORE IS NOT ALWAYS BETTER - A CASE FOR LOW-DOSE LEUCOVORIN - REPLY

      Journal of clinical oncology
    52. SARTOR O; ROBBINS KC
      SUBSTRATE-SPECIFICITY FOR NORMAL BUT NOT MUTATIONALLY ACTIVATED VARIANTS OF SRC FAMILY KINASES

      The Journal of biological chemistry
    53. WORLAND PJ; KAUR G; STETLERSTEVENSON M; SEBERS S; SARTOR O; SAUSVILLE EA
      ALTERATION OF THE PHOSPHORYLATION STATE OF P34(CDC2) KINASE BY THE FLAVONE L86-8275 IN BREAST-CARCINOMA CELLS - CORRELATION WITH DECREASED H1 KINASE-ACTIVITY

      Biochemical pharmacology


ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 20/01/21 alle ore 18:45:32